Please login to the form below

DAM and CMS: managing assets to maximise adoption and value

Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised to maximise outcomes for pharma and agencies.
As we watch the world of healthcare marketing shift into the digital era, we see new opportunities beginning to emerge for pharma to target their customers with novel, exciting and innovative content. Alongside this shift, there is the growing need to deliver this content in the quickest way possible. This digital revolution is setting the scene for a faster, cleaner and more effective use of marketing content, which minimises time and cost without compromising on quality.

While we look towards the possibilities that this transition offers, so too must we look at the systems that will be supporting the delivery and uptake of these files – this is where digital asset management (DAM) and content management systems (CMS) come into the mix.

Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised to maximise outcomes for pharma and agencies.


What is DAM and who uses it?
Digital asset management (DAM) is a system that supports the distribution of digital assets among users. It is the bridge that delivers revolutionary, breakthrough information to continually content-hungry users. In this industry, any stakeholder within the complex network of healthcare could be a user, and it’s these connections between users where DAM has the opportunity to thrive.

What is a CMS and how is it different from DAM?
 When discussing DAM, it is necessary to recognise the role of content management systems (CMS) and understand the difference between the two. While DAM supports the delivery of assets between users, CMS facilitates the uptake and use of these assets. For example, a DAM system would allow an advertising agency to deliver an advert to multiple media publishers throughout a region. A CMS then informs those publishers of how to edit and format the adverts for their different channels, as well as how to apply search criteria so that their customers can view the adverts easily.

How can we use DAM/CMS?
The two systems work together to provide insight into the true value of an asset, by demonstrating how it is being used across a network of users. Furthermore, DAM/CMS systems are continuing to evolve alongside the development of technology, resulting in an expansion in the types of assets that can be shared across networks. This growth fuels the competitiveness of the industry by encouraging users to share the most ground-breaking and high quality assets in the quickest time possible. The question is: what makes the systems worthy of the investment in the first place, and what value do the users gain?



Download the full article from Blue Latitude Health

19th September 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health